AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7985177 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy without respiratory training mask
Number of subjects: 16
Study 7985177 — intervention group
Group type: COMPARATOR
Intervention: Follow-up on mask usage
Number of subjects: 16
Study 3068597 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiderm growth factor (EGF)
Number of subjects: 11
Study 3068597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31711921 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 156
Study 31711921 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 1 mg
Number of subjects: 156
Study 31711921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 30095630 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone sheets
Number of subjects: 0
Study 30095630 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel
Number of subjects: 0
Study 28005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival approach without canthotomy in association with transoral maxillary approach and lateral rim skin incision without canthotomy (group 1)
Number of subjects: 10
Study 28005755 — intervention group
Group type: COMPARATOR
Intervention: Traditional subciliar incision at lower eyelid and vertical lateral incision at lateral margin of the orbit (group 2)
Number of subjects: 10
Study 24217994 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessionally delivered, telephonic‐based psycho‐educational intervention
Number of subjects: 199
Study 24217994 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study 22814485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 104
Study 22814485 — intervention group
Group type: COMPARATOR
Intervention: Standard fasting regimen
Number of subjects: 104
Study 20546271 — intervention group
Group type: EXPERIMENTAL
Intervention: Supper (15-g carbohydrate dairy snack before bed)
Number of subjects: 35
Study 20546271 — intervention group
Group type: COMPARATOR
Intervention: No supper
Number of subjects: 35
Study 18937661 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin for 14 days
Number of subjects: 43
Study 18937661 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 14 days
Number of subjects: 43
Study 18937661 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study 15865113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiology (intravenous cholangiography or magnetic resonance cholangiography)
Number of subjects: 312
Study 15865113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiology)
Number of subjects: 312
Study 12848204 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: Fluid restriction, avoidance of routine sedation, higher doses of mannitol
Number of subjects: 0
Study 12848204 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted fluid supplementation, routine sedation, lower doses of mannitol (only when needed) for GCS ≤ 8
Number of subjects: 0
Study 12848204 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal fluid restriction and normal sodium supplementation for GCS > 8
Number of subjects: 0
Study 11461095 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 0
Study 11461095 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 0
Study 9202359 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitors
Number of subjects: 0
Study 9202359 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8123347 — intervention group
Group type: EXPERIMENTAL
Intervention: Past CIS procedure (general information and cessation materials)
Number of subjects: 382
Study 8123347 — intervention group
Group type: COMPARATOR
Intervention: Modified CIS stage-model procedure (counseling specific to smoking-cessation stage)
Number of subjects: 382
Study 3327846 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg body weight of i.v. IgG on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months
Number of subjects: 20
Study 3327846 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 2695288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal contraceptive sponge used only during the fertile time
Number of subjects: 0
Study 2695288 — intervention group
Group type: COMPARATOR
Intervention: Vaginal contraceptive sponge used at every intercourse
Number of subjects: 0
Study 30814670 — intervention group
Group type: EXPERIMENTAL
Intervention: RC14-GR1
Number of subjects: 207
Study 30814670 — intervention group
Group type: EXPERIMENTAL
Intervention: LGG-BB12
Number of subjects: 207
Study 27550953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg once daily for 12 weeks
Number of subjects: 180
Study 27550953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 27550953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (exploratory study)
Number of subjects: 180
Study 27550953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (exploratory study)
Number of subjects: 180
Study 25789738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (20 min of moderate-intensity)
Number of subjects: 77
Study 25789738 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (20 min)
Number of subjects: 77
Study 25789738 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 77
Study 23598699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted ocular vestibular evoked myogenic potentials (oVEMPs) testing using a BC stimulus at frequencies of 250 and 500 Hz.
Number of subjects: 27
Study 21167327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT)
Number of subjects: 50
Study 21167327 — intervention group
Group type: COMPARATOR
Intervention: No nasojejunal tube (NJT)
Number of subjects: 50
Study 19487706 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐based multirisk assessment report attached to the medical chart
Number of subjects: 293
Study 19487706 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 293
Study 17410412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg)
Number of subjects: 18
Study 17410412 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microg/kg)
Number of subjects: 18
Study 17410412 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg)
Number of subjects: 18
Study 28332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 12
Study 28332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dilution hemodiafiltration (pre-HDF)
Number of subjects: 12
Study 11549103 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 26
Study 11549103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 26
Study 11549103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined doses of piperacillin and tobramycin
Number of subjects: 26
Study 11549103 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin alone or with tazobactam
Number of subjects: 26
Study 9549737 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cannulation (Group E)
Number of subjects: 150
Study 9549737 — intervention group
Group type: COMPARATOR
Intervention: Late cannulation (Group L)
Number of subjects: 150
Study 7860471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 60
Study 7860471 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg twice daily
Number of subjects: 60
Study 3220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 30
Study 31638719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management (NLCM)
Number of subjects: 96
Study 31638719 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 96
Study 31328466 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for radical hysterectomy (RH)
Number of subjects: 0
Study 31328466 — intervention group
Group type: COMPARATOR
Intervention: Open radical hysterectomy (RH)
Number of subjects: 0
Study 27982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation/Activation factor at baseline
Number of subjects: 235
Study 27982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 235
Study 27982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher global functioning at baseline
Number of subjects: 235
Study 27982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in Stimulation/Activation factor from baseline to 12-month follow-up
Number of subjects: 235
Study 27982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in Stimulation/Activation factor over time
Number of subjects: 235
Study 26596627 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX), a single intravenous injection of 3 mg/kg
Number of subjects: 35
Study 26596627 — intervention group
Group type: COMPARATOR
Intervention: Placebo, a single saline serum injection
Number of subjects: 35
Study 23945572 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified treatment regimens for severe infection
Number of subjects: 3600
Study 21988066 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA)
Number of subjects: 537
Study 18301331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (dietician referral, exercise program, weight loss advice) in Group 1 (n=36 total: 28 IGT + 8 NODAT)
Number of subjects: 111
Study 18301331 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification leaflets in Group 2 (n=79)
Number of subjects: 111
Study 16525071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 62
Study 16525071 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 62
Study 14732978 — intervention group
Group type: EXPERIMENTAL
Intervention: CuBE-PLA-NP
Number of subjects: 26
Study 14732978 — intervention group
Group type: COMPARATOR
Intervention: CuBE
Number of subjects: 26
Study 16836290 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT combined with radiosurgery
Number of subjects: 27
Study 16836290 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 27
Study 8780576 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 118
Study 8780576 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid placebo
Number of subjects: 118
Study 1512328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (10 mg bolus, then 90 mg over 2 h) followed by heparin
Number of subjects: 36
Study 1512328 — intervention group
Group type: COMPARATOR
Intervention: Heparin (continuous infusion rate of 1,750 IU/h)
Number of subjects: 36
Study 1512328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 36
Study 1512328 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 36
Study 6240405 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200-110 (2.5 mg, 5.0 mg, 10.0 mg)
Number of subjects: 12
Study 6240405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31706395 — intervention group
Group type: EXPERIMENTAL
Intervention: Resettle
Number of subjects: 72
Study 31706395 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 72
Study 28637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intention to take up any type of HIV testing
Number of subjects: 141
Study 28637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefit of HIV testing
Number of subjects: 141
Study 28637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived psychological barriers of HIV testing
Number of subjects: 141
Study 28637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy in taking up HIV testing
Number of subjects: 141
Study 28637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived cue to action from non-governmental organization staff
Number of subjects: 141
Study 27126252 — intervention group
Group type: EXPERIMENTAL
Intervention: Drill instrument
Number of subjects: 10
Study 27126252 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 10
Study 25149141 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mindset induction
Number of subjects: 0
Study 25149141 — intervention group
Group type: COMPARATOR
Intervention: Fixed mindset induction
Number of subjects: 0
Study 23250532 — intervention group
Group type: EXPERIMENTAL
Intervention: Local immunomodulator (0.04% synthetic tetradecapeptide solution)
Number of subjects: 75
Study 23250532 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic modalities
Number of subjects: 75
Study 20462428 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g raw walnuts/d for 6 weeks
Number of subjects: 21
Study 20462428 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g raw walnuts/d for 6 weeks
Number of subjects: 21
Study 18765001 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (90 mg, once daily)
Number of subjects: 200
Study 18765001 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone tablets (200 mg, three times daily)
Number of subjects: 200
Study 15983221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 252
Study 15983221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 12503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent stretching device
Number of subjects: 0
Study 11019474 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment (day care)
Number of subjects: 121
Study 11019474 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (hospital admission)
Number of subjects: 121
Study 11019474 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of outpatient treatment
Number of subjects: 121
Study 7492487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine G
Number of subjects: 0
Study 7492487 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study 2334155 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of norfloxacin alone
Number of subjects: 12
Study 2334155 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin 5 min after aluminum‐magnesium hydroxide (Maalox)
Number of subjects: 12
Study 2334155 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 2 h after 400 mg of norfloxacin
Number of subjects: 12
Study 2334155 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin 5 min after calcium carbonate (Titralac)
Number of subjects: 12
Study 2334155 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid administration
Number of subjects: 12
Study 348210 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine with intermittent positive pressure
Number of subjects: 14
Study 348210 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 31101323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 84633
Study 31101323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (after excluding patients with prior myocardial infarction or heart failure)
Number of subjects: 84633
Study 31101323 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 84633
Study 31101323 — intervention group
Group type: COMPARATOR
Intervention: Thiazides
Number of subjects: 84633
Study 28588686 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) for 24 hours
Number of subjects: 38
Study 28588686 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 38
Study 25602877 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-parent intervention emphasizing adolescent-parent communication
Number of subjects: 2564
Study 25602877 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only goal-setting intervention
Number of subjects: 2564
Study 25602877 — intervention group
Group type: COMPARATOR
Intervention: No parent intervention
Number of subjects: 2564
Study 23995030 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic management (PM)
Number of subjects: 69
Study 23995030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (paroxetine)
Number of subjects: 69
Study 23995030 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT)
Number of subjects: 69
Study 23995030 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 69
Study 20500133 — intervention group
Group type: EXPERIMENTAL
Intervention: Education booklet on bra fit and breast support from a sports physiotherapist
Number of subjects: 115
Study 20500133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 115
Study 18162932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (arm B)
Number of subjects: 18
Study 18162932 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (arm A)
Number of subjects: 18
Study 16608616 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 130
Study 16608616 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 130
Study 12880730 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana leaf dressing (BLD)
Number of subjects: 30
Study 12880730 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze (VG)
Number of subjects: 30
Study 11052924 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) 400000 i.u. administered intramuscularly to 6 patients
Number of subjects: 34
Study 11052924 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 patients not given RP)
Number of subjects: 34
Study 1341892 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (1KE or 5KE) administered one or 3 times every other day
Number of subjects: 39
Study 1341892 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (repeated injections)
Number of subjects: 39
Study 1341892 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (doses more than 5 KE)
Number of subjects: 39
Study 6230953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 72
Study 6230953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 72
Study 6230953 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 72
Study 6230953 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 72
Study 31518224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 18
Study 31518224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30084892 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-term lotteries for 13 weeks
Number of subjects: 163
Study 30084892 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lotteries combined with an additional long-term lottery after 26 weeks
Number of subjects: 163
Study 30084892 — intervention group
Group type: COMPARATOR
Intervention: Control arm without lotteries
Number of subjects: 163
Study 26995281 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month digital health weight loss intervention including algorithm-generated tailored behavior change goals, self-monitoring via mobile technologies, daily self-weighing using a network-connected scale, skills training materials, 18 counseling phone calls with a Track coach, and primary care provider counseling.
Number of subjects: 351
Study 26995281 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (control group)
Number of subjects: 351
Study 24651209 — intervention group
Group type: EXPERIMENTAL
Intervention: VIB + PT (physiotherapy plus vibration)
Number of subjects: 30
Study 24651209 — intervention group
Group type: COMPARATOR
Intervention: SHAM + PT (physiotherapy and sham vibration)
Number of subjects: 30
Study 22018075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training model (1 year)
Number of subjects: 0
Study 22018075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training model (nearly 3 years)
Number of subjects: 0
Study 20197161 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional hyrax tooth‐borne expander
Number of subjects: 62
Study 20197161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone‐anchored expander
Number of subjects: 62
Study 20197161 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 16899376 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ring-like cue presented immediately after subjective disappearance of the target in MIB, radius systematically modulated.
Number of subjects: 0
Study 16899376 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering cue at 1Hz with a critically small radius.
Number of subjects: 0
Study 16899376 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt onset of a small square cue.
Number of subjects: 0
Study 16087696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus gemcitabine (PG)
Number of subjects: 565
Study 16087696 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 565
Study 12126240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 300
Study 12126240 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 300
Study 10639654 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (dynamic protocol under supervision, 9 sessions of 30 min each over 3 weeks)
Number of subjects: 20
Study 10639654 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (verbal and written advice and exercises)
Number of subjects: 20
Study 11540403 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/70 kg d-methamphetamine
Number of subjects: 30
Study 11540403 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg d-methamphetamine
Number of subjects: 30